In this issue:
Auto-HCT in elderly patients
Romidepsin/bortezomib/dexamethasone in relapsed/refractory MM
Three regimens for newly diagnosed MM
Predictors of loss of CR after ASCT
Renal impairment as prognostic factor in novel agent regimens
Allogeneic vs. autologous second HSCT
Maintenance thalidomide
Bortezomib regimen in high genetic risk MM
Induction VD vs. vtD in newly diagnosed MM
CyBorD in AL amyloidosis
Please login below to download this issue (PDF)